




The relative strengths and weaknesses of Sagent Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sagent Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 107% points. The greatest weakness of Sagent Pharmaceuticals Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is 339%, being 118% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	147,268
Cost of Goods Sold	0
Intangible Assets	4,277
Liabilities, Current	40,454
Liabilities, Non-Current	6.0
Other Assets	19,990
Other Compr. Net Income	338
Other Expenses	153,446
Other Liabilities	0
Other Net Income	243
Other Revenues	183,615
Property and Equipment	780
Research and Development	17,136
Selling, General and Administrative Expense	30,093

Output Variable	Value in 1000 USD
Assets	172,315
Liabilities	40,460
Expenses	200,675
Revenues	183,615
Stockholders Equity	131,855
Net Income	-16,817
Comprehensive Net Income	-16,648
BaseVar	298,823
ECR before Limited Liability	255%
Economic Capital Ratio	339%